CORE C: Clinical and Data Management Core (UC Berkeley, University of Michigan, Sustainable Sciences Institute) SUMMARY The Clinical and Data Management Core (Core C) will be instrumental for the success of the P01 Program. First, the Core will continue to conduct the Pediatric Dengue Cohort Study in Managua, Nicaragua. This cohort study is the longest continuous cohort study of dengue and as such is an invaluable source of samples and clinical data from children with natural repeat dengue virus (DENV) infections. Both retrospectively and prospectively collected samples and data will be available to the P01 Projects. Core C will oversee all aspects of running the Cohort Study including enrollment, sample collection and storage, data collection and management, quality control, provision of medical care, and human subjects documentation. Second, Core C will coordinate the compilation of clinical data and the distribution of samples available from the P01 Program dengue studies in Nicaragua and the Philippines, where a cohort study of children vaccinated with the Dengvaxia dengue vaccine is ongoing. To this end, the Core will design, maintain, update and oversee the P01 Program databases, which will include clinical data, sample characteristics and availability. Core C will provide tailored data sets and assist in selection of analysis-specific biological specimens, ensuring efficient data sharing and sample distribution through the implementation of high levels of quality control. This will include having a data manager at the University of Michigan (UM) who will compile the data from the clinical sites and use it to assemble data sets, including the creation of any necessary variables for P01 Program sites. Core C personnel at UC Berkeley will be responsible for receiving samples from Nicaragua, maintaining an inventory, and distributing the samples to P01 Projects in response to requests and in coordination with the data manager at UM. Third, the Core will maintain a copy of immunological data generated through the Projects 1-3 and Core B and will deposit data into ImmPort. P01 investigators will be able to submit data for upload to and download data from the database, facilitating the flow of information across all P01 Program partners.
Aim 1 is to continue conducting the community-based prospective Pediatric Dengue Cohort Study in Managua, Nicaragua.
Aim 2 is to coordinate clinical data compilation, integration and distribution, and shipment of clinical samples, and to perform phylogenetic sequencing.
Aim 3 is to manage data generated through the P01 and to deposit immunological data generated through the P01 Projects and Cores into ImmPort. Taken together, the Clinical and Data Management Core will play an essential role in the P01 Program by providing data and samples to scientific Projects for the ultimate purpose of identifying both natural and vaccine-induced immune correlates of protection against dengue disease.
(CORE C) Dengue is a major health problem worldwide and is complicated by 4 distinct yet cross-reactive serotypes. This P01 addresses the critical need to improve understanding of human B and T cell responses to dengue virus infection and vaccination and identify immune correlates of protection from or susceptibility to disease. Core C will continue the Nicaraguan Pediatric Dengue Cohort Study to provide key samples from natural repeat dengue virus infections. It will also ensure efficient management and distribution of samples and data from the cohort and other human subject studies to Projects, collaborate on the selection of samples, and maintain P01 databases and the project workspace.
|Burger-Calderon, Raquel; Gonzalez, Karla; Ojeda, Sergio et al. (2018) Zika virus infection in Nicaraguan households. PLoS Negl Trop Dis 12:e0006518|
|Tsai, Wen-Yang; Youn, Han Ha; Tyson, Jasmine et al. (2018) Use of Urea Wash ELISA to Distinguish Zika and Dengue Virus Infections. Emerg Infect Dis 24:1355-1359|
|Gallichotte, Emily N; Baric, Thomas J; Yount Jr, Boyd L et al. (2018) Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog 14:e1006934|
|Katzelnick, Leah C; Harris, Eva (2018) The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection. Curr Opin Virol 29:51-61|
|Goncalves, Adriana; Peeling, Rosanna W; Chu, May C et al. (2018) Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report. J Infect Dis 217:1060-1068|
|de Silva, Aravinda M; Harris, Eva (2018) Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harb Perspect Biol 10:|
|Weiskopf, Daniela; Grifoni, Alba; Arlehamn, Cecilia S Lindestam et al. (2018) Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua. Hum Immunol 79:1-2|
|Andrade, Daniela V; Harris, Eva (2018) Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure. Virus Res 254:27-33|
|Tan, Yi; Pickett, Brett E; Shrivastava, Susmita et al. (2018) Differing epidemiological dynamics of Chikungunya virus in the Americas during the 2014-2015 epidemic. PLoS Negl Trop Dis 12:e0006670|
|Premkumar, Lakshmanane; Collins, Matthew; Graham, Stephen et al. (2018) Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. J Clin Microbiol 56:|
Showing the most recent 10 out of 54 publications